HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Zantac Recall: Sanofi Heeds To Potential Ranitidine Contaminant

Executive Summary

Firm opts for recall "as a precautionary measure due to inconsistencies in preliminary test results of the active ingredient used in the US and Canadian products." Other firms marketing ranitidine in US have started recalls due to concerns about NDMA since potential problem became known in September.

You may also be interested in...



Sanofi Returning Zantac OTC Heartburn Remedy Brand To US Market Formulated With Famotidine

Along with its Q1 results including a 7.3% drop in consumer health sales to 1.11bn ($1.35bn), Sanofi announces 10-mg famotidine tablets branded Zantac 360° will be available in the US in June.

Sanofi Overcomes Zantac Troubles To Gain Share In US

Sanofi Consumer Healthcare has been gaining share in the US OTC market since October 2020 after putting behind it long running Zantac troubles, according to business head Julie Van Ongevalle.

Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines

Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel